Results 71 to 80 of about 48,562 (198)

Experimental Pharmacological Management of Psoriasis

Journal of Experimental Pharmacology, 2021
Elena Campione,1 Terenzio Cosio,1 Monia Di Prete,2 Caterina Lanna,1 Annunziata Dattola,1 Luca Bianchi1 1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2Anatomic Pathology, University of Rome Tor ...
Campione E, Cosio T, Di Prete M, Lanna C, Dattola A, Bianchi L   +5 more
doaj  

Clinical significance of Janus Kinase inhibitor selectivity [PDF]

Rheumatology, 2018
Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: JAK1, JAK2, JAK3 and TYK2.
openaire   +3 more sources

IGF-1 and PDGF-bb suppress IL-1β-induced cartilage degradation through down-regulation of NF-κB signaling: involvement of Src/PI-3K/AKT pathway. [PDF]

, 2011
Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that plays a key role in the pathogenesis of osteoarthritis (OA). Growth factors (GFs) capable of antagonizing the catabolic actions of cytokines may have therapeutic potential in the treatment of OA.
Franziska Busch, Azadeh Montaseri, Jafar Soleimani Rad, Busch, Franziska, Montaseri, Azadeh, Rad, Jafar Soleimani, Mehdi Shakibaei, Ali Mobasheri, Constance Aldinger, Aldinger, Constance, Shakibaei, Mehdi, Mobasheri, Ali, Constanze Buhrmann, Buhrmann, Constanze   +13 more
core   +1 more source

Characteristics of eligible studies utilizing Janus kinase inhibitors for the cicatricial alopecia treatment.

Characteristics of eligible studies utilizing Janus kinase inhibitors for the cicatricial alopecia treatment.
Azadeh Goodarzi (3433010), Sara Sadeghi (14319696), Nima Hajizadeh (17941317), Amirhossein Heidari (17941320)   +3 more
core   +1 more source

Assay Development and Inhibitor Screening for Janus Kinase 2 [PDF]

, 2023
Janus kinase 2 (JAK2) is an essential mediator of hematopoietic and growth signaling in cells. It signals as a part of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway, which ultimately regulates gene expression by
Pölläniemi, Angelika
core  

The suitability of treating atopic dermatitis with Janus kinase inhibitors

, 2022
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant morbidity and reduced quality of life, especially in patients with moderate-severe AD. Recently, topical and oral Janus kinase (JAK)-inhibitors were investigated
Silverberg, Jonathan I, Narla, Shanthi
core   +1 more source

Negative patch test findings after initiation of upadacitinib: A case report

SAGE Open Medical Case Reports
Upadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis.
Meghan L McPhie, Melanie D Pratt, Mark G Kirchhof   +2 more
doaj   +1 more source

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

Frontiers in Immunology, 2019
Autoimmune skin diseases are characterized by significant local and systemic inflammation that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway.
Michael D. Howell, Fiona I. Kuo, Paul A. Smith   +2 more
doaj   +1 more source

Hyperlipidaemic effect of Janus kinase inhibitors: a meta-analysis

, 2019
Introduction: Janus kinase (JAK) inhibitors are effective in treating rheumatoid arthritis. However, JAK is involved in lipid metabolism, so we investigated the association between JAK inhibitors and hyperlipidaemia.
Tsoi, MF, Cheung, TT, Cheung, BMY
core  

Diversifying the triquinazine scaffold of a Janus kinase inhibitor

RSC Medicinal Chemistry
Diversifying the sp 3 -rich triquinazine core, we prepared four new chiral scaffolds and 26 analogues that reveal how subtle structural changes modulate Janus Kinase activity, yielding a potent JAK1 inhibitor comparable to FDA-approved drugs.
Kleni Mulliri, Kris Meier, Johanna-Dorothea Feuchter, Sacha Javor, Matheus A. Meirelles, Jean-Louis Reymond   +5 more
openaire   +2 more sources